Okay, let's tackle this question about low molecular weight heparin (LMWH). The question is asking which of the options is an example of LMWH. First, I need to recall what LMWHs are. They are derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller molecules. This makes them more predictable in their anticoagulant effect and allows for subcutaneous administration without routine monitoring.

The core concept here is understanding the classification of anticoagulants, specifically the differences between unfractionated heparin (UFH) and LMWH. LMWHs have a lower molecular weight (around 4,000-6,000 Da) compared to UFH (15,000-30,000 Da). They primarily inhibit factor Xa and have less effect on thrombin (factor IIa) compared to UFH. Common examples include enoxaparin, dalteparin, and tinzaparin.

Now, looking at the options provided, even though they aren't listed here, common distractors in such questions might include UFH (like heparin sodium), direct thrombin inhibitors (e.g., dabigatran), or even other anticoagulants like warfarin. The correct answer should be one of the LMWHs mentioned earlier. For example, enoxaparin is a classic LMWH used in deep vein thrombosis prevention and treatment.

The incorrect options would be other anticoagulants. For instance, option A might be UFH, which is not LMWH. Option B could be a direct oral anticoagulant (DOAC) like rivaroxaban. Option C might be an antiplatelet agent like aspirin, and Option D could be a vitamin K antagonist like warfarin. Each of these has different mechanisms and uses compared to LMWHs.

The clinical pearl here is remembering the LMWHs by their suffixes, like "-parin" (enoxaparin, dalteparin), which helps in quick identification. Also, LMWHs are preferred over UFH in many settings due to their safety profile and ease of use without frequent monitoring.

**Core Concept**
Low molecular weight heparins (LMWHs) are derived from unfractionated heparin (UFH) via depolymerization, resulting in smaller chains with predictable anticoagulant effects. They primarily inhibit factor Xa and have a lower risk of heparin-induced thrombocytopenia (HIT) compared to UFH.

**Why the Correct Answer is Right**
Enoxaparin is a prototypical LMWH. It binds antithrombin III to enhance inhibition of factor Xa, with minimal effect on thrombin (factor IIa). Its subcutaneous administration, longer half-life (~4–5 hours), and reduced need for routine monitoring make it a first-line agent for DVT prophylaxis and treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** Heparin sodium (UFH) has variable bioavailability and requires intravenous/intramuscular administration with frequent aPTT monitoring.
**Option B:** Dabigatran is a direct thrombin inhibitor (DOAC), unrelated to heparin derivatives.
**Option C:** War

✓ Correct Answer: C. Enoxaparin